Three new synthetic cannabinoids caused seizures, aggression, and severe toxicity in mice at doses far lower than THC

Combined in vitro and in vivo study. In vitro: competition binding experiments for CB1/CB2 affinity and potency; neurotoxicity testing in mouse neuro-2a cells. In vivo: behavioral and neurological assessment in male CD-1 mice comparing the three synthetics with THC and JWH-018, with CB1 antagonist (AM251) challenge to confirm receptor mechanisms.

These third-generation synthetic cannabinoids are sold as "legal" alternatives to cannabis but are orders of magnitude more potent. The seizure and aggression profile seen in this study matches clinical reports of severe reactions in human users. Understanding their pharmacology is essential for emergency medicine and toxicology.

The synthetic cannabinoid market continuously produces new compounds designed to evade drug scheduling. Each generation tends to be more potent and less predictable than the last. This study documents the toxicological profile of three such compounds, providing reference data for clinicians and regulators. The seizure and aggression findings explain why synthetic cannabinoid emergencies often look nothing like natural cannabis intoxication.

Animal study using injected synthetic cannabinoids at controlled doses. Human users often smoke these compounds with unknown purity and dosing. The mouse model may not capture all human-relevant effects. Only male mice were tested. Long-term effects were not assessed.